CoChat

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Open access
Lv, Jicheng, Liu, Lijun, Hao, Chuanming, Li, Guisen, Fu, Ping, Xing, Guangqun, Zheng, Hongguang, Chen, Nan, Wang, Caili, Luo, Ping, Xie, Deqiong, Zuo, Li, Li, Rongshan, Mao, Yonghui, Dong, Shaoshao, Zhang, Pengfei, Zheng, Huixiao, Wang, Yue, Qin, Wei, Wang, Wenxiang, Li, Lin, Jiao, Wenjuan, Fang, Jianmin, Zhang, Hong · 2023 · Kidney International Reports
Cited by 197

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Introduction To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of transmembrane activator and calcium-modulating cyclophilin ligand interactor and fragment crystallizable portion of immunoglobulin G (IgG), which neutralizes the B lymphocyte stimulator and a proliferation-inducing ligand. Methods This phase 2 randomized placebo-controlled trial aimed to evaluate the efficacy and safety of telitacicept in patients with IgAN. Participants with an estimated glomerular filtration rate (eGFR) >35 ml/min per 1.73 m 2 and proteinuria ≥0.75 g/d despite optimal supportive therapy, were randomized 1:1:1 to receive subcutaneous telitacicept 160 mg, telitacicept 240 mg, or placebo weekly for 24 weeks. The primary end point was the change in 24-hour proteinuria at week 24 from baseline. Results Forty-four participants were randomized into placebo ( n = 14), telitacicept 160 mg ( n = 16), and telitacicept 240 mg ( n = 14) groups. Continuous reductions in serum IgA, IgG, and IgM levels were observed in the telitacicept group. Telitacicept 240 mg therapy reduced mean proteinuria by 49% from baseline (change in proteinuria vs. placebo, 0.88; 95% confidence interval, −1.57 to −0.20; P = 0.013), whereas telitacicept 160 mg reduced it by 25% (−0.29; 95% confidence interval, −0.95 to 0.37; P = 0.389). The eGFR remained stable over time. Adverse events (AEs) were similar in all groups. Treatment-emergent AEs were mild or moderate, and no severe AEs were reported. Conclusion Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ekir.2022.12.014

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 197

Metadata

Authors
Lv, J., Liu, L., Hao, C., Li, G., Fu, P., Xing, G., Zheng, H., Chen, N., Wang, C., Luo, P., Xie, D., Zuo, L., Li, R., Mao, Y., Dong, S., Zhang, P., Zheng, H., Wang, Y., Qin, W., Wang, W., Li, L., Jiao, W., Fang, J., & Zhang, H.
Venue
Kidney International Reports
Publisher
Elsevier BV
Published
2023-03
Volume
8
Issue
3
Pages
499-506
ISSN
2468-0249 (ISSN-L)
OpenAlex
W4313334095
Cited by
197
References
2
FWCI
17.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. https://app.cochat.ai/papers/10.1016/j.ekir.2022.12.014
The paper
Lv, J., Liu, L., Hao, C., Li, G., Fu, P., Xing, G., Zheng, H., Chen, N., Wang, C., Luo, P., Xie, D., Zuo, L., Li, R., Mao, Y., Dong, S., Zhang, P., Zheng, H., Wang, Y., Qin, W., . . . Zhang, H. (2023). Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney International Reports. https://doi.org/10.1016/j.ekir.2022.12.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.